市場調查報告書
商品編碼
1441281
人乳寡糖(HMO) 全球市場規模、佔有率、成長分析(按類型、按應用) - 產業預測,2023-2030 年Global Human Milk Oligosaccharides (HMO) Market Size, Share, Growth Analysis, By Type(2'-FL & 3-FL, Sialyllactose), By Application(Segmented as, Infant Formula) - Industry Forecast 2023-2030 |
2022年全球人乳寡糖(HMO)市場規模為1.7791億美元,預計將從2023年的 1.9517 億美元成長到2031年的 4.0932 億美元,預測期內(2024-2031年)年複合成長率為 9.7%。。
人乳寡糖(HMO)市場已被視為嬰兒健康和營養的關鍵組成部分。 HMO 屬於複雜碳水化合物,天然存在於母乳中,具有多種健康益處。這些生物活性化合物支持嬰兒免疫系統、胃腸道健康和認知發展。隨著對 HMO 認知的不斷深入,其潛在應用範圍已從嬰兒營養擴展到醫療、機能性食品和益生元補充品等領域。提高大眾對 HMO 健康益處的認知以及使嬰兒配方奶粉更接近母乳的目標是市場成長的關鍵驅動力。 HMO 增強免疫和腸道健康的能力與自然和整體治療方法的成長趨勢不謀而合。研究和開發還包括識別和開發針對特定健康益處的獨特 HMO 組合物。然而,HMO 生產的複雜性和成本帶來了挑戰,特別是在複製母乳中存在的各種 HMO 方面。監管考慮和潛在的智慧財產權障礙也會影響市場動態。隨著 HMO 研究的進展,市場不僅在嬰兒營養方面顯示出前景,而且在滿足不同生命階段的各種健康需求方面也顯示出前景。重新定義營養和健康概念的潛力凸顯了 HMO 市場在塑造醫藥和機能性食品未來的重要性。
Global Human Milk Oligosaccharides (HMO) Market size was valued at USD 177.91 Million in 2022 and is poised to grow from USD 195.17 Million in 2023 to USD 409.32 Million by 2031, at a CAGR of 9.7% during the forecast period (2024-2031).
The market for human milk oligosaccharides (HMOs) is gaining prominence as a crucial component in infant wellness and nutrition. HMOs, categorized as complex carbohydrates, naturally occur in human breast milk and offer various health benefits. These bioactive compounds support the development of the infant's immune system, gastrointestinal health, and cognitive functions. As our understanding of HMOs expands, their potential applications extend beyond infant nutrition to fields like medicine, functional foods, and prebiotic supplements. Increasing public awareness of the health benefits of HMOs and the aim to make infant formula more akin to breast milk are key drivers of market growth. The ability of HMOs to enhance immunological and gut health aligns with the rising trend of seeking natural and holistic remedies. Research focus also includes identifying and developing unique HMO compositions to target specific health benefits. However, challenges in HMO production complexity and cost arise, particularly in replicating the diverse range of HMOs present in breast milk. Regulatory considerations and potential intellectual property obstacles also influence market dynamics. As research on HMOs advances, the market shows promise not just in infant nutrition but also in addressing various health needs across different stages of life. The potential to redefine the concept of nutrition and well-being underscores the significance of the HMO market in shaping the future of healthcare and functional foods.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Milk Oligosaccharides (HMO) and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.
Global Human Milk Oligosaccharides (HMO) Market Segmental Analysis
The Human Milk Oligosaccharides (HMO) Market is segmented on the basis of Type, Application, and Region. Based on Type, the market is segmented as, 2'-FL & 3-FL, Sialyllactose, LNT & LNnT. Based on Application the market is segmented as, Infant Formula, Functional Food & Beverages, Food/Medical Supplements, Others. Regional the market is segmented as, North America, Asia Pacific, Latin America, and Middle East & Africa (MEA)
Drivers of the Global Human Milk Oligosaccharides (HMO) Market
The increasing recognition of the health benefits of human milk oligosaccharides (HMOs) is a significant driver for market growth. There is a rising demand for HMO-fortified products due to the role HMOs play in enhancing the immune system, cognitive development, and gut health in infants, as well as potential benefits for adults.
The incorporation of HMOs in formula products reflects consumers' desire for infant formulas that closely mimic the health advantages of breast milk. HMOs have become a vital component of infant nutrition as parents seek to provide their babies with optimal nourishment.
Restraints in the Global Human Milk Oligosaccharides (HMO) Market
The synthesis of HMOs is a challenging and intricate process. The scalability and cost-efficiency of manufacturing HMOs are hindered by the intricate and expensive methods required to replicate the diverse array of HMO structures found in breast milk.
It is essential to educate consumers about the benefits and importance of HMOs, especially in non-infant applications. While challenging, increasing awareness and understanding of the potential uses of HMOs is crucial for market growth.
Market Trends of the Global Human Milk Oligosaccharides (HMO) Market
Exploring Diverse Applications Beyond Infant Nutrition: While HMOs have traditionally been associated with infant feeding and are naturally present in breast milk, there is a growing trend to explore their potential in various other contexts. Researchers are investigating the use of HMOs in functional foods, dietary supplements, and pharmaceuticals to address a range of health conditions across different age groups.
Customization and HMO Profiling: As scientific understanding of HMOs advances, an increasing number of HMO profiles are being developed to closely mimic the composition of HMOs found in the breast milk of specific mothers. This customization offers the potential to provide new-borns with personalized nutrition tailored to their individual needs, as each mother's milk has a unique HMO composition.